Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 ...

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at bayer.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

Bayer's KERENDIA® (finerenone) received FDA approval as the first new treatment in over 30 years for adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), reducing urinary albumin-to-creatinine ratio to slow disease progression.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You now face a market opened by a rare FDA nod for type 1 diabetes kidney disease after 30 years. Secure early access and focus on integrating KERENDIA’s mechanism into your CKD offerings before competitors react.

◆ Coverage

2 sources · 17 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalckd-treatmenttype-1-diabetesbayermedical-innovation